Last reviewed · How we verify
Monocid (CEFONICID)
At a glance
| Generic name | CEFONICID |
|---|---|
| Drug class | cefonicid |
| Target | Matrix metalloproteinase-9 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1984 |
Approved indications
- Bacterial infection due to Klebsiella pneumoniae
- Bacterial septicemia
- Escherichia coli urinary tract infection
- Haemophilus influenzae pneumonia
- Infection due to Staphylococcus aureus
- Infection of bone
- Infection of skin AND/OR subcutaneous tissue
- Infectious disorder of joint
- Klebsiella cystitis
- Lower respiratory tract infection
- Morganella Morganii Urinary Tract Infection
- Osteomyelitis due to Staphylococcus aureus
- Pneumonia
- Pneumonia due to Escherichia coli
- Pneumonia due to Streptococcus
- Prevention of Perioperative Infection
- Prosthetic Arthroplasty Infection Prevention
- Proteus urinary tract infection
- Providencia Urinary Tract Infection
- Septicemia due to Escherichia coli
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |